NASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ONCT Stock Alerts $8.25 -0.29 (-3.40%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$8.20▼$8.9950-Day Range$7.80▼$10.1552-Week Range$5.57▼$13.14Volume6,862 shsAverage Volume11,923 shsMarket Capitalization$22.19 millionP/E RatioN/ADividend YieldN/APrice Target$31.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Oncternal Therapeutics alerts: Email Address Oncternal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside279.8% Upside$31.33 Price TargetShort InterestHealthy0.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 6 Articles This WeekInsider TradingAcquiring Shares$92,736 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($10.67) to ($9.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 starsMedical Sector459th out of 907 stocksPharmaceutical Preparations Industry209th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingOncternal Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncternal Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.52% of the float of Oncternal Therapeutics has been sold short.Short Interest Ratio / Days to CoverOncternal Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncternal Therapeutics has recently decreased by 17.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncternal Therapeutics does not currently pay a dividend.Dividend GrowthOncternal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCT. Previous Next 1.9 News and Social Media Coverage News SentimentOncternal Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Oncternal Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncternal Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,736.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Oncternal Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.05% of the stock of Oncternal Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncternal Therapeutics are expected to grow in the coming year, from ($10.67) to ($9.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncternal Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncternal Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncternal Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Oncternal Therapeutics Stock (NASDAQ:ONCT)Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Read More ONCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCT Stock News HeadlinesApril 11, 2024 | insidertrades.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Acquires $27,650.56 in StockApril 2, 2024 | insidertrades.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills Purchases 6,914 SharesApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 25, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)April 19, 2024 | uk.finance.yahoo.comEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline DrugsApril 18, 2024 | globenewswire.comOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerApril 18, 2024 | americanbankingnews.comQ1 2024 Earnings Forecast for Oncternal Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ONCT)April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)April 17, 2024 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.comApril 16, 2024 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Price Target Cut to $28.00 by Analysts at HC WainwrightApril 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming CatalystsApril 14, 2024 | insidermonkey.com5 Buy-Rated Stocks with Latest Insider PurchasesApril 11, 2024 | finance.yahoo.comAIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USAMarch 15, 2024 | globenewswire.comOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerMarch 13, 2024 | markets.businessinsider.comNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)March 10, 2024 | finance.yahoo.comOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 8, 2024 | finance.yahoo.comQ4 2023 Oncternal Therapeutics Inc Earnings CallMarch 8, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | benzinga.comOncternal Therapeutics's Earnings: A PreviewMarch 7, 2024 | msn.comONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Oncternal Therapeutics Q4 EarningsMarch 7, 2024 | washingtonpost.comOncternal Therapeutics: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | markets.businessinsider.comOncternal Therapeutics earnings: here's what to expectFebruary 29, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCT CUSIPN/A CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees27Year FoundedN/APrice Target and Rating Average Stock Price Target$31.33 High Stock Price Target$40.00 Low Stock Price Target$26.00 Potential Upside/Downside+279.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($13.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,480,000.00 Net Margins-5,029.17% Pretax Margin-5,029.17% Return on Equity-95.87% Return on Assets-83.56% Debt Debt-to-Equity RatioN/A Current Ratio6.94 Quick Ratio6.94 Sales & Book Value Annual Sales$790,000.00 Price / Sales28.09 Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book0.81Miscellaneous Outstanding Shares2,690,000Free Float2,474,000Market Cap$22.19 million OptionableOptionable Beta1.26 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Comp: $814.67kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Comp: $549.21kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Comp: $524.48kDr. Rajesh Krishnan Ph.D. (Age 50)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentAnita WisethSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsCytoMed TherapeuticsNASDAQ:GDTCCumberland PharmaceuticalsNASDAQ:CPIXBiora TherapeuticsNASDAQ:BIORBullfrog AINASDAQ:BFRGLumos PharmaNASDAQ:LUMOView All CompetitorsInsidersRobert James WillsBought 3,086 shares on 4/8/2024Total: $27,650.56 ($8.96/share)Robert James WillsBought 6,914 shares on 3/28/2024Total: $58,630.72 ($8.48/share)David F HaleBought 714 shares on 2/23/2024Total: $6,454.56 ($9.04/share)Gunnar F KaufmannBought 150 shares on 6/14/2023Total: $1,080.00 ($7.20/share)Gunnar F KaufmannBought 1,250 shares on 6/12/2023Total: $8,750.00 ($7.00/share)View All Insider Transactions ONCT Stock Analysis - Frequently Asked Questions Should I buy or sell Oncternal Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ONCT shares. View ONCT analyst ratings or view top-rated stocks. What is Oncternal Therapeutics' stock price target for 2024? 3 equities research analysts have issued 1 year price targets for Oncternal Therapeutics' stock. Their ONCT share price targets range from $26.00 to $40.00. On average, they predict the company's stock price to reach $31.33 in the next year. This suggests a possible upside of 279.8% from the stock's current price. View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts. How have ONCT shares performed in 2024? Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of 2024. Since then, ONCT shares have decreased by 23.1% and is now trading at $8.25. View the best growth stocks for 2024 here. Are investors shorting Oncternal Therapeutics? Oncternal Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 13,800 shares, a decrease of 17.4% from the March 31st total of 16,700 shares. Based on an average daily trading volume, of 9,400 shares, the short-interest ratio is currently 1.5 days. Approximately 0.5% of the shares of the stock are short sold. View Oncternal Therapeutics' Short Interest. When is Oncternal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ONCT earnings forecast. How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) issued its earnings results on Thursday, March, 7th. The company reported ($3.11) earnings per share for the quarter, missing the consensus estimate of ($3.09) by $0.02. The business earned $0.30 million during the quarter, compared to analysts' expectations of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative trailing twelve-month return on equity of 95.87%. During the same period last year, the firm earned ($4.00) earnings per share. When did Oncternal Therapeutics' stock split? Shares of Oncternal Therapeutics reverse split before market open on Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX). How do I buy shares of Oncternal Therapeutics? Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
